TY - JOUR
T1 - A genetics-first approach to dissecting the heterogeneity of autism
T2 - Phenotypic comparison of autism risk copy number variants
AU - IMAGINE-ID Consortium
AU - Chawner, Samuel J.R.A.
AU - Doherty, Joanne L.
AU - Anney, Richard J.L.
AU - Antshel, Kevin M.
AU - Bearden, Carrie E.
AU - Bernier, Raphael
AU - Chung, Wendy K.
AU - Clements, Caitlin C.
AU - Curran, Sarah R.
AU - Cuturilo, Goran
AU - Fiksinski, Ania M.
AU - Gallagher, Louise
AU - Goin-Kochel, Robin P.
AU - Gur, Raquel E.
AU - Hanson, Ellen
AU - Jacquemont, Sebastien
AU - Kates, Wendy R.
AU - Kushan, Leila
AU - Maillard, Anne M.
AU - McDonald-McGinn, Donna M.
AU - Mihaljevic, Marina
AU - Miller, Judith S.
AU - Moss, Hayley
AU - Pejovic-Milovancevic, Milica
AU - Schultz, Robert T.
AU - Green-Snyder, Lee Anne
AU - Vorstman, Jacob A.
AU - Wenger, Tara L.
AU - Hall, Jeremy
AU - Owen, Michael J.
AU - van den Bree, Marianne B.M.
N1 - Funding Information:
Prof. Hall has received research grant support from AbbVie, A&Z Pharmaceutical, Pfizer, Takeda Pharmaceuticals, and Wyeth. Profs. Owen and van den Bree have received research grant support from Takeda Pharmaceuticals. The other authors report no financial relationships with commercial interests.
Funding Information:
Supported by the Baily Thomas Charitable Trust (grant 2315/1), the Brain Canada Foundation, the Canada Research Chair in Genetics of Neuro-developmentalDisorders,theCanadianInstituteofHealthResearch(grant 400528/159734), Health and Care Research Wales (grant 507556), the Medical Research Council Centre (grant G0801418), the Medical Research Council Programme (grant G0800509), the Medical Research Council studentship (grant 1499282), NIMH (grants 5UO1MH101724, MH064824, RO1 MH085953, and U01MH101719), the Simons Foundation (SFARI Explorer Award), the Simons Foundation Autism Research Initiative, the Swiss National Science Foundation (grant PMPDP3_171331), the United Kingdom Medical Research Council and Medical Research Foundation (grants MR/L011166/1 and MR/N022572/1), the Waterloo Foundation (grant WF918-1234), Wellcome Trust Fellowship (grant 505714), Wellcome Trust ISSF, and a Wellcome Trust Strategic Award. Collaboration with the University of Belgrade was funded by European COST Action (CA16210), Maximizing Impact of research in NeuroDevelopmental DisorderS (MINDDS). The IMAGINE-ID consortium member list is presented in the online supplement. The authors thank the main funders of the Autism Genome Project: Autism Speaks (U.S.), the Canadian Institutes of Health Research, the Health Research Board (Ireland), Genome Canada, the Hilibrand Foundation (U.S.), the Medical Research Council (U.K.), and the Ontario Genomics Institute. The authors also thank all the children and families who took part in this study; the United Kingdom National Health Service medical genetic clinics; charities including Max Appeal, 22Crew, and Unique; all members of the IMAGINE-ID consortium; the core laboratory team of the Division of Psychological Medicine and Clinical Neurosciences laboratory at Cardiff University, for DNA sample management and genotyping; all of the families at the participating Simons Variation in Individuals Project (VIP) sites; the 16p11.2 European consortium; Belgrade University Children’s Hospital; the International 22q11.2 Brain and Behaviour Consortium; and the National Centre for Mental Health.
Funding Information:
Supported by the Baily Thomas Charitable Trust (grant 2315/1), the Brain Canada Foundation, the Canada Research Chair in Genetics of Neurodevelopmental Disorders, the Canadian Institute of Health Research (grant 400528/159734), Health and Care Research Wales (grant 507556), the Medical Research Council Centre (grant G0801418), the Medical Research Council Programme (grant G0800509), the Medical Research Council studentship (grant 1499282), NIMH (grants 5UO1MH101724, MH064824, RO1 MH085953, and U01MH101719), the Simons Foundation (SFARI Explorer Award), the Simons Foundation Autism Research Initiative, the Swiss National Science Foundation (grant PMPDP3_171331), the United Kingdom Medical Research Council and Medical Research Foundation (grants MR/L011166/1 and MR/N022572/1), the Waterloo Foundation (grant WF918-1234), Wellcome Trust Fellowship (grant 505714), Wellcome Trust ISSF, and a Wellcome Trust Strategic Award. Collaboration with the University of Belgrade was funded by European COST Action (CA16210), Maximizing Impact of research in NeuroDevelopmental DisorderS (MINDDS). The IMAGINE-ID consortium member list is presented in the online supplement.
Publisher Copyright:
© 2021 American Psychiatric Association. All rights reserved.
PY - 2021/1
Y1 - 2021/1
N2 - Objective: Certain copy number variants (CNVs) greatly increase the risk of autism. The authors conducted a genetics-first study to investigate whether heterogeneity in the clinical presentation of autism is underpinned by specific genotype-phenotype relationships. Methods: This international study included 547 individuals (mean age, 12.3 years [SD=4.2], 54% male) who were ascertained on the basis of having a genetic diagnosis of a rare CNV associated with high risk of autism (82 16p11.2 deletion carriers, 50 16p11.2 duplication carriers, 370 22q11.2 deletion carriers, and 45 22q11.2 duplication carriers), as well as 2,027 individuals (mean age, 9.1 years [SD=4.9], 86% male) with autism of heterogeneous etiology. Assessments included the Autism Diagnostic Interview-Revised and IQ testing. Results: The four genetic variant groups differed in autism symptom severity, autism subdomain profile, and IQ profile. However, substantial variability was observed in phenotypic outcome in individual genetic variant groups (74%-97% of the variance, depending on the trait), whereas variability between groups was low (1%-21%, depending on the trait). CNV carriers who met autism criteria were compared with individuals with heterogeneous autism, and a range of profile differences were identified. When clinical cutoff scores were applied, 54% of individuals with one of the four CNVs who did not meet full autism diagnostic criteria had elevated levels of autistic traits. Conclusions: Many CNV carriers do not meet full diagnostic criteria for autism but nevertheless meet clinical cutoffs for autistic traits. Although profile differences between variants were observed, there is considerable variability in clinical symptoms in the same variant.
AB - Objective: Certain copy number variants (CNVs) greatly increase the risk of autism. The authors conducted a genetics-first study to investigate whether heterogeneity in the clinical presentation of autism is underpinned by specific genotype-phenotype relationships. Methods: This international study included 547 individuals (mean age, 12.3 years [SD=4.2], 54% male) who were ascertained on the basis of having a genetic diagnosis of a rare CNV associated with high risk of autism (82 16p11.2 deletion carriers, 50 16p11.2 duplication carriers, 370 22q11.2 deletion carriers, and 45 22q11.2 duplication carriers), as well as 2,027 individuals (mean age, 9.1 years [SD=4.9], 86% male) with autism of heterogeneous etiology. Assessments included the Autism Diagnostic Interview-Revised and IQ testing. Results: The four genetic variant groups differed in autism symptom severity, autism subdomain profile, and IQ profile. However, substantial variability was observed in phenotypic outcome in individual genetic variant groups (74%-97% of the variance, depending on the trait), whereas variability between groups was low (1%-21%, depending on the trait). CNV carriers who met autism criteria were compared with individuals with heterogeneous autism, and a range of profile differences were identified. When clinical cutoff scores were applied, 54% of individuals with one of the four CNVs who did not meet full autism diagnostic criteria had elevated levels of autistic traits. Conclusions: Many CNV carriers do not meet full diagnostic criteria for autism but nevertheless meet clinical cutoffs for autistic traits. Although profile differences between variants were observed, there is considerable variability in clinical symptoms in the same variant.
UR - http://www.scopus.com/inward/record.url?scp=85098706549&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098706549&partnerID=8YFLogxK
U2 - 10.1176/appi.ajp.2020.20010015
DO - 10.1176/appi.ajp.2020.20010015
M3 - Article
C2 - 33384013
AN - SCOPUS:85098706549
SN - 0002-953X
VL - 178
SP - 77
EP - 86
JO - American Journal of Psychiatry
JF - American Journal of Psychiatry
IS - 1
ER -